IOMP Webinar: Radiopharmaceutical Therapy (RPT)

IOMP Webinar: Radiopharmaceutical Therapy (RPT)
Wednesday, 25th October 2023 at 12 pm GMT; Duration 1 hour
NEW: CME/CPD credit point shall be awarded for participation in the webinar in full.
Register here
To check the corresponding time in your country please check this link:
greenwichmeant...
Organizer: M Mahesh
Moderator: M Mahesh
Speakers: Rob Hobbs/George Sgouros and Ana Kiess
Topic 1: Imaging and Dosimetry in Radiopharmaceutical therapy
Even after they have made it to Phase I clinical trial investigation, 97% of new cancer drugs fail. The majority of these drugs are chosen based on their ability to inhibit cell signaling pathways responsible for maintaining a cancer phenotype. Although this approach has led to dramatic improvements in treatment efficacy for certain cancers, this approach to cancer therapy is more complex than initially appreciated. Radiopharmaceutical therapy (RPT) involves the targeted delivery of radiation to tumor cells or to the tumor microenvironment. Since the radionuclides used in RPT also emit photons, nuclear medicine imaging may be used to measure the pharmacokinetics of the therapeutic agent and estimate tumor and normal organ absorbed doses in individual patients to implement an individualized (precision medicine) treatment planning approach to RPT delivery. This unique feature of RPT, along with its ability to delivery highly potent alpha-particle radiation to targeted cells, is at the heart of what distinguishes RPT compared to other cancer treatments for widespread metastases.
Learning Objectives:
Understand the mechanism of Radiopharmaceutical therapy.
Compare and contrast RPT with other cancer therapy modalities.
Understand the distinction between RPT and Theranostics.
Topic 2: Clinical Radiopharmaceutical Therapy, Dose-Response and Future Directions
Radiopharmaceuticals are rapidly expanding in clinical use and development for prostate cancer and many other tumor types. As in other radiation therapies, there is a dose-response relationship for both tumor and normal tissues, with increasing responses or toxicities at higher absorbed doses. In this webinar, we will discuss these concepts in relation to currently approved radiopharmaceutical therapies (RPTs) and future directions of RPTs. We will also review clinical indications and practical use of currently approved RPTs including [177Lu] Lu-PSMA-617, [177Lu] Lu-DOTATATE, and [223Ra] RaCl2.
Learning Objectives:
Understand clinical indications and practical use of currently approved radiopharmaceutical therapies
Discuss concepts of radiation dose and response of tumors and normal organ toxicities
Explore future directions of clinical radiopharmaceutical therapies.